Heidelberg Pharma AG (XTER:HPHA) Cash-to-Debt : 190.94 (As of Feb. 2024)

View and export this data going back to 2006. Start your Free Trial

What is Heidelberg Pharma AG Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Heidelberg Pharma AG's cash to debt ratio for the quarter that ended in Feb. 2024 was 190.94.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Heidelberg Pharma AG could pay off its debt using the cash in hand for the quarter that ended in Feb. 2024.

The historical rank and industry rank for Heidelberg Pharma AG's Cash-to-Debt or its related term are showing as below:

XTER:HPHA' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.58 Med: 84.84 Max: No Debt
Current: 190.94

During the past 13 years, Heidelberg Pharma AG's highest Cash to Debt Ratio was No Debt. The lowest was 0.58. And the median was 84.84.

XTER:HPHA's Cash-to-Debt is ranked better than
82.05% of 1493 companies
in the Biotechnology industry
Industry Median: 6.89 vs XTER:HPHA: 190.94

Heidelberg Pharma AG Cash-to-Debt Historical Data

The historical data trend for Heidelberg Pharma AG's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Heidelberg Pharma AG Cash-to-Debt Chart

Heidelberg Pharma AG Annual Data

Trend

Nov14

Nov15

Nov16

Nov17

Nov18

Nov19

Nov20

Nov21

Nov22

Nov23

Cash-to-Debt

Get a 7-Day Free Trial

No Debt

24.54

0.58

5.09

7.45

Heidelberg Pharma AG Quarterly Data
	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24
Cash-to-Debt	Get a 7-Day Free Trial															382.42	5.39	8.80	7.45	190.94

Competitive Comparison of Heidelberg Pharma AG's Cash-to-Debt

For the Biotechnology subindustry, Heidelberg Pharma AG's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Heidelberg Pharma AG's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Heidelberg Pharma AG's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Heidelberg Pharma AG's Cash-to-Debt falls into.

Heidelberg Pharma AG Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Heidelberg Pharma AG's Cash to Debt Ratio for the fiscal year that ended in Nov. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	43.439	/	(5.761	+	0.07)
	=	7.45

Heidelberg Pharma AG's Cash to Debt Ratio for the quarter that ended in Feb. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	32.65	/	(0.101	+	0.07)
	=	190.94

Heidelberg Pharma AG (XTER:HPHA) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Heidelberg Pharma AG Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Heidelberg Pharma AG's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Heidelberg Pharma AG (XTER:HPHA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Heidelberg Pharma AG (XTER:HPHA) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

HPHA:Germany HPHA:Germany HPHA:Germany

Address

Gregor-Mendel-Street 22, Ladenburg, DEU, 68526

Website

https://www.heidelberg-pharma.com

Heidelberg Pharma AG is a biopharmaceutical company. It is focused on oncology and develops the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology platform and advances the biological mode of action of the toxin as a novel therapeutic principle. The proprietary lead candidate is HDP-101 which is a BCMA (B-cell maturation antigen) - ATAC for multiple myeloma. In addition, the company offers preclinical contract research services. It operates through the following business divisions: Customer Specific Research, Diagnostics, and TherapeuticS.

Executives

Prof. Dr. Andreas Pahl

Board of Directors

Heidelberg Pharma AG (XTER:HPHA) Headlines

No Headlines